Welcome to the Chronic Hepatitis B Drug Development Summit

The first ever meeting purpose-built for discussing the advancement of curative therapies for chronic HBV infection

Traditional antiviral approaches meet next-generation immunotherapy at this industry-led assembly of biotech and pharma leaders. Since the successful design and delivery of a functional cure for HCV in the form of a novel DAA combination; HBV has been brought to the centre stage.

This action packed two day agenda holds 13 Presentations from industry and academic leaders, 2 interactive panel/roundtable discussions, one interactive HCC workshop and over 4 hours of networking, you can join the only platform discussing issues present in the development of curative HBV therapeutics. 

Join this critical global forum which will again be uniting industry specialists from Pharma, Biotechs, Academia and Solution Providersas we target the most pressing issues important to bringing the next generation HBV drugs to market. 


Expert Speakers at Chronic Hepatitis B Drug Development Summit Include:

Chari Cohen

Senior Vice President

Hepatitis B Foundation

Eduardo Bruno Martins

Vice President - Clinical Development


Melissa Palmer

Chief Medical Officer

Gannex Pharma Ltd. A wholly owned subsidiary of Ascletis Pharma LLC

Stephane Daffis

Scientist II

Gilead Sciences